Shanghai Henlius Biotech, Inc. announced that it will present the latest clinical data of two of its products, HANSIZHUANG (serplulimab) and HLX22, at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. HANSIZHUANG, the world’s first anti-PD-1 monoclonal antibody for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), has been approved in China and several Southeast Asian countries. It is also under review by the European Medicines Agency (EMA) for the first-line treatment of ES-SCLC. HLX22, an innovative anti-HER2 monoclonal antibody, has shown promising results in combination with trastuzumab and chemotherapy for HER2-positive gastric cancer patients.
HANSIZHUANG (serplulimab)
- Title: Updated efficacy and subgroup analysis of first-line serplulimab plus bevacizumab and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: a phase 2/3 study
- Session: Poster Session C: Cancers of the Colon, Rectum, and Anus
- Presentation Number: 170
- Onsite Poster display date: 2025/1/25
- Leading PI: Rui-Hua Xu, Sun Yat-sen University Cancer Center
HLX22
- Title: HLX22 plus trastuzumab and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): Updated results with additional patients
- Session: Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
- Presentation Number: 440
- Onsite Poster display date: 2025/1/23
- Leading PI: Jin Li, Shanghai GoBroad Cancer Hospital
The presentations will highlight the safety and efficacy of these treatments, with a focus on their application in first-line therapy for various cancer types. Henlius continues to advance its research in immuno-oncology, with over 10 clinical trials initiated and more than 4,800 subjects enrolled worldwide.
